Table 2 Main words and sentences per word class – Classes 1 to 4
CLASS 1 (34.32%) - Aspects related to the disease (clinical study evidence) | CLASS 2 (33.58%) Aspects related to incorporating the drug | CLASS 3 (14.76%) – Aspects related to treatment (MEDICATION) | CLASS 4: 94 TS (17.34%) – Right and access to the drug | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Cat. 4 – individual cont. (χ2 128.39) | Cat. 2 – Pharmaceutical Ind. (χ2 132.26) and Cat. 3 Health Prof. (χ2 3.7) | Cat. 3 – Health Prof. (χ2 48.35) and Cat. 1- Patient Rep./adv (χ2 14.55) | Cat. 4 – individual cont. (χ2 32.95) | ||||||||
Main Words | χ2 | Illustrative Excerpt | Main Words | χ2 | Illustrative Excerpt | Main Words | χ2 | Illustrative Excerpt | Main Words | χ2 | Illustrative Excerpt |
Breast Cancer | 272.95 | “however more than 60 of these women will die from recurrence of the disease in other organs. Three types of systemic adjuvant postoperative therapy have proved to be effective at significantly lowering the chance of breast cancer recurring after curative surgery” | Herceptin | 52.29 | “position of the Oncoguia institute regarding the CONITEC document that addresses the approval of Trastuzumab for early-stage breast cancer. Herceptin Trastuzumab is indicated for the treatment of patients with early-stage her2-positive breast cancer either before surgery as neoadjuvant treatment or after surgery as adjuvant treatment” | Disease-Free Survival | 157.72 | “and subsequently as an isolated drug or concomitantly to hormone therapy until completing a total of one year of treatment. The change in the text is justified by the fact that, based on studies published to date, Trastuzumab concomitantly to chemotherapy exhibits better results than when the drug is administered only after chemotherapy” | National Health System | 383.38 | “additionally, according to the studies mentioned, it is recommended that Trastuzumab be administered for a period of one year and as such, Femama believes that national health system patients should receive the complete treatment in the same manner as patients with health insurance plans” |
Disease | 178.77 | Patient | 51.29 | Overall Survival | 126.16 | Incorporation | 259.1 | ||||
Death | 124.75 | Clinical | 38.95 | Change | 113.71 | Health Insurance | 124.91 | ||||
Malignant | 112.44 | CONITEC | 36.83 | Arm | 113.71 | Indisputable | 118.33 | ||||
Organ | 107.75 | Recommendation | 35.12 | Docetaxel | 95.21 | Coverage Type | 112.24 | ||||
Significantly | 103.74 | Data | 34.72 | Paclitaxel | 89.09 | Complete | 106.6 | ||||
Metastasis | 102.21 | Indicated | 30.51 | Text | 76.92 | Benefit | 88.47 | ||||
Occurrence | 102.21 | Roche | 28.43 | Justify | 76.92 | Medication | 87.11 | ||||
Rationale | 101.41 | Consider | 27.58 | Isolated | 63.66 | Brazil | 84.63 | ||||
Molecular | 101.41 | Safety | 26.35 | No | 61 | Need | 73.02 | ||||
Recurrence | 93.82 | Cross | 26.35 | Chemotherapy | 60.41 | Duty | 53.99 | ||||
Risk | 90.22 | Her2-Positive | 25.54 | Difference | 52.85 | Femama | 44.34 | ||||
Development | 85.07 | Presentation | 24.27 | Demonstrate | 50.37 | Take | 28.92 | ||||
Surgery | 82.03 | Diagnosis | 24.27 | Regime | 46.89 | Add | 28.92 | ||||
Women | 68.19 | Adverse | 24.27 | Complete | 46.89 | Reversible | 28.92 | ||||